Advertisement

Investigational New Drugs

, Volume 21, Issue 1, pp 63–74 | Cite as

A Phase I Clinical Trial of Spicamycin Derivative KRN5500 (NSC 650426) Using a Phase I Accelerated Titration “2B” Design

  • S.M. Gadgeel
  • R.R. Boinpally
  • L.K. Heilbrun
  • A. Wozniak
  • V. Jain
  • B. Redman
  • M. Zalupski
  • R. Wiegand
  • R. Parchment
  • P.M. LoRusso
Article

Abstract

The spicamycin derivative KRN5500 was considered as a potential anti-cancer agent based on in vitro and preclinical studies. A Phase I study involving 24 cancer patients in whom tumors were refractory to all other conventional therapies was conducted to determine the dose limiting toxicity, maximum tolerated dose, effectiveness, and pharmacokinetic parameters of this drug administered by 1-h IV infusion daily for five consecutive days every 3 weeks. Using an accelerated dose titration strategy, 8.4 mg/m2/d × 5 days was the maximum administered dose. Severe gastrointestinal and hepatic toxicities were observed at doses at or above 4.3 mg/m2/d × 5. The recommended Phase II dose is 4.3 mg/m2/d × 5. The distribution of KRN5500 followed a two-compartment model, and clearance did not decrease significantly over the dose range 0.8–8.4 mg/m2/d × 5. No significant correlation was observed between plasma levels and toxicity. No tumor responses were observed among the 14 patients evaluable for response.

Phase I clinical trial MTD toxicity clearance pharmacokinetics half-life hepatotoxicity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hayakawa Y, Nakagawa M, Kawai H, Tanabe K, Nakayama H, Shimazu A, Seto H, Otake N: Studies on the differentiation inducers of myeloid leukemic cells. III. Spicamycin, a new inducer of differentiation of HL-60 human promyelocytic leukemia cells. J Antibiot (Tokyo) 36(7): 934–937, 1983Google Scholar
  2. 2.
    Kawasaki K, Murakami T, Ita M, Sasaki K, Furukawa S: KRN5500, a novel antitumor agent, induces apoptosis or cell differentiation in HL-60 cells. Cytometry 39(3): 211–216, 2000Google Scholar
  3. 3.
    Kamishohara M, Kawai H, Sakai T, Uchida T, Tsuruo T, Otake N: Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen. Cancer Chemother Pharmacol 38(6): 495–498, 1996Google Scholar
  4. 4.
    Kamishohara M, Kawai H, Odagawa A, Isoe T, Mochizuki J, Uchida T, Hayakawa Y, Seto H, Tsuruo T, Otake N: Structure-antitumor activity relationship of semi-synthetic spicamycin analogues. J Antibiot (Tokyo) 46(9): 1439–1446, 1993Google Scholar
  5. 5.
    Kamishohara M, Kawai H, Odagawa A, Isoe T, Mochizuki J, Uchida T, Hayakawa Y, Seto H, Tsuruo T, Otake N: Antitumor activity of SPM VIII, a derivative of the nucleoside antibiotic spicamycin, against human tumor xenografts. J Antibiot (Tokyo), 47(11): 1305–1311, 1994Google Scholar
  6. 6.
    Lee YS, Nishio K, Ogasawara H, Funayama Y, Ohira T, Saijo N: In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines. Cancer Res 55(5): 1075–1079, 1995Google Scholar
  7. 7.
    Stine KC, Warren BA, Saylors RL, Becton DL: KRN5500 induces apoptosis (PCD) of myeloid leukemia cell lines and patient blasts. Leuk Res 24(9): 741–749, 2000Google Scholar
  8. 8.
    Zhang WJ, Ohnishi K, Yoshida H, Pan L, Maksumova L, Muratkhodjaev F, Luo JM, Shigeno K, Fujisawa S, Naito K, Nakamura S, Shinjo K, Takeshita A, Ohno R: Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein. Jpn J Cancer Res 91(6): 604–611, 2000Google Scholar
  9. 9.
    Burger AM, Kaur G, Hollingshead M, Fischer RT, Nagashima K, Malspeis L, Duncan KL, Sausville EA: Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro. Clin Cancer Res 3(3): 455–463, 1997Google Scholar
  10. 10.
    Kamishohara M, Kawai H, Sakai T, Isoe T, Hasegawa K, Mochizuki J, Uchida T, Kataoka S, Yamaki H, Tsuruo T: Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells. Oncol Res 6(8): 383–390, 1994Google Scholar
  11. 11.
    Kawai H: Protein synthesis inhibitor — antitumor activity and mode of action of KRN5500. Gan To Kagaku Ryoho 24(11): 1571–1577, 1997Google Scholar
  12. 12.
    Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89(15): 1138–1147, 1997Google Scholar
  13. 13.
    Hollander M, Wolfe DA: Nonparametric Statistical Methods. John Wiley and Sons Inc., New York, NY, 1973Google Scholar
  14. 14.
    Mehta C and Patel N: StatXact 5 Statistical Software for Exact Nonparametric Inference. Cytel Corp., Cambridge, MA, 2001Google Scholar
  15. 15.
    Yoshioka E, Morino M, Tanaka H, Shinkai H: Manual and automatic extraction and high-performance liquid chromatographic determination of a spicamycin derivative, KRN5500, in rat plasma. J Chromatogr B Biomed Sci Appl 691(2): 371–375, 1997Google Scholar
  16. 16.
    Levi F, Giacchetti S, Zidani R, Brezault-Bonnet C, Tigaud JM, Goldwasser F, Misset JL: Chronotherapy of colorectal cancer metastases. Hepatogastroenterology 48(38): 320–322, 2001Google Scholar
  17. 17.
    Matsumura Y, Yokoyama M, Kataoka K, Okano T, Sakurai Y, Kawaguchi T, Kakizoe T: Reduction of the side effects of an antitumor agent, KRN5500, by incorporation of the drug into polymeric micelles. Jpn J Cancer Res 90(1): 122–128, 1999Google Scholar
  18. 18.
    Misset JL, Levi F: Chronotherapy with 5–fluorouracil and other drugs in gastrointestinal malignancies. Chronotherapy Group of the European Organization for Research and Treatment of Cancer. Semin Oncol 27(5 Suppl 10): 78–82, 2000Google Scholar
  19. 19.
    Levi F: Therapeutic implications of circadian rhythms in cancer patients. Novartis Found Symp 227: 119–136; discussion 136–142, 2000Google Scholar
  20. 20.
    Takama H, Tanaka H, Sudo T, Tamura T, Tanigawara Y: Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study. Cancer Chemother Pharmacol 47(5): 404–410, 2001Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • S.M. Gadgeel
    • 1
  • R.R. Boinpally
    • 1
  • L.K. Heilbrun
    • 1
  • A. Wozniak
    • 1
  • V. Jain
    • 1
  • B. Redman
    • 2
  • M. Zalupski
    • 2
  • R. Wiegand
    • 1
  • R. Parchment
    • 1
  • P.M. LoRusso
    • 1
  1. 1.Barbara Ann Karmanos Cancer InstituteWayne State UniversityDetroitUSA
  2. 2.University of Michigan Cancer CenterAnn ArborUSA

Personalised recommendations